APHT Aphton (MM)

Aphton Corporation (NASDAQ:APHT), a biotechnology company focused on the development of immunotherapies for the treatment of cancer, announced today that Patrick Mooney, M.D., Chairman and CEO, will present an overview of the company at the upcoming UBS Global Life Sciences Conference to be held at the Grand Hyatt in New York City. Dr. Mooney's presentation will be on Tuesday, September 27th at 3:30 p.m. EDT. A live audio webcast of the presentation can be accessed by visiting the UBS conference website at www.ibb.ubs.com. A replay of the presentation will begin 3 hours after the actual presentation and will be available until October 29, 2005. About Aphton Aphton Corporation, headquartered in Philadelphia, Pennsylvania is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Aphton's products seek to empower the body's own immune system to fight disease. Through the acquisition of Igeneon AG in March 2005, Aphton acquired late-stage products, IGN101, a cancer vaccine designed to induce an immune response against EpCAM positive tumor cells, and IGN311, a fully humanized antibody against the Lewis Y antigen. Aphton has strategic alliances with Xoma for treating gastrointestinal and other gastrin-sensitive cancers using anti-gastrin monoclonal and other antibodies; Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits; and sanofi-aventis for the development and commercialization of Insegia (G17DT immunogen) related to cancers of the gastrointestinal system and other cancers in North America and Europe. Aphton is also currently seeking other partners that will support the further development of Insegia. For more information about Aphton or its programs please visit Aphton's website at www.aphton.com.